Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
12.82
-0.20 (-1.54%)
Apr 22, 2026, 4:00 PM EDT - Market closed
Amneal Pharmaceuticals Revenue
In the year 2025, Amneal Pharmaceuticals had annual revenue of $3.02B with 8.05% growth. Amneal Pharmaceuticals had revenue of $814.32M in the quarter ending December 31, 2025, with 11.47% growth.
Revenue (ttm)
$3.02B
Revenue Growth
+8.05%
P/S Ratio
1.44
Revenue / Employee
$346,984
Employees
8,700
Market Cap
4.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.02B | 224.80M | 8.05% |
| Dec 31, 2024 | 2.79B | 400.35M | 16.73% |
| Dec 31, 2023 | 2.39B | 181.31M | 8.20% |
| Dec 31, 2022 | 2.21B | 118.63M | 5.67% |
| Dec 31, 2021 | 2.09B | 101.15M | 5.08% |
| Dec 31, 2020 | 1.99B | 366.15M | 22.51% |
| Dec 31, 2019 | 1.63B | -36.62M | -2.20% |
| Dec 31, 2018 | 1.66B | 629.34M | 60.89% |
| Dec 31, 2017 | 1.03B | 15.42M | 1.51% |
| Dec 31, 2016 | 1.02B | 151.95M | 17.54% |
| Dec 31, 2015 | 866.28M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.27B |
| Hims & Hers Health | 2.35B |
| Lantheus Holdings | 1.54B |
| Alkermes | 1.48B |
| Phibro Animal Health | 1.46B |
| Prestige Consumer Healthcare | 1.10B |
| BioCryst Pharmaceuticals | 874.84M |
| Supernus Pharmaceuticals | 718.95M |
AMRX News
- 9 hours ago - Amneal Pharma to buy Kashiv BioSciences in $1.1 billion deal - Reuters
- 9 hours ago - Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader - Business Wire
- 10 hours ago - Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance - GlobeNewsWire
- 2 days ago - Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson's Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY® - GlobeNewsWire
- 8 days ago - Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S. - GlobeNewsWire
- 13 days ago - Amneal Launches Bimatoprost Ophthalmic Solution, 0.01% - GlobeNewsWire
- 15 days ago - Amneal to Report First Quarter 2026 Results on May 1, 2026 - GlobeNewsWire
- 15 days ago - Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson's Awareness Month - GlobeNewsWire